Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

Big Five Numbers

Accendra Health, Inc. growth analysis

Start with the long-run numbers that show whether ACH compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/A-34.8%-74.2%
Equity
N/AN/AN/AN/A
Cash
N/AN/A+59.5%+471.0%
ROIC
N/A4.0%1.1%8.4%

Analysis

Latest growth is strongest in Cash at +471.0% and weakest in Revenue at -74.2%. Three-year average ROIC is 1.1%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-34.8%
-2.4% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/A+1.7%
+5.1% (5yr)2 analysts

Analysis

Recent growth has been strongest in EBIT at +1.7% over three years. Forward estimates point to EBIT at +5.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where ACH earns its revenue, as reported in company filings

This company does not report revenue segments.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$102.7M
+ D&A$214.5M
+ Stock-Based Comp$12.9M
- Deferred Tax-$17.9M
+ Working Capital$65.2M
- Other Non-Cash-$273.8M
= Operating Cash Flow-$101.8M
- Capex-$201.3M
= Free Cash Flow-$303.1M

Analysis

FY2025 free cash flow is -$303.1M. FCF conversion is 295.2% of net income. Operating cash flow was -$101.8M, with capex of -$201.3M. The largest bridge item is Other Non-Cash at -$273.8M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for ACH.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

No analyst ratings available.

Competitor growth

How does Accendra Health, Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

Aclaris Therapeutics, Inc.

ACRS

$719.27M—+3.8%-35.9%
+59.9% (5yr)5 analysts

Allogene Therapeutics, Inc.

ALLO

$569.51M———
—5 analysts

Sight Sciences, Inc.

SGHT

$485.88M—+22.9%+2.7%
+11.7% (4yr)2 analysts

Canopy Growth Corporation

CGC

$397.46M+43.9%-2.4%+13.2%
-8.2% (6yr)1 analysts

Editas Medicine, Inc.

EDIT

$395.93M+37.9%-14.9%+27.1%
-13.5% (5yr)5 analysts

Cabaletta Bio, Inc.

CABA

$337.52M———
—7 analysts

BioAge Labs Inc.

BIOA

$265.43M———
+35.1% (5yr)4 analysts

High Tide Inc.

HITI

$245.16M—+48.1%+18.5%
+10.1% (5yr)1 analysts

CVRx, Inc.

CVRX

$71.65M—+56.4%+36.1%
+16.8% (5yr)2 analysts

Outset Medical, Inc.

OM

$56.54M—+19.1%+1.2%
+10.2% (5yr)2 analysts

Questions

Growth questions

Common questions about ACH's growth, answered from reported and forecast figures.

Is ACH growing revenue?

Revenue declined 74.2% year over year, from $10.70B to $2.76B.

Is ACH turning growth into profit?

The latest net margin is -39.8%, which shows how much revenue became net income.